Van ECK Associates Corp grew its holdings in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 1.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,443 shares of the medical equipment provider’s stock after buying an additional 500 shares during the quarter. Van ECK Associates Corp’s holdings in Hologic were worth $2,867,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the business. Heritage Financial Services LLC purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $27,000. Glassman Wealth Services raised its holdings in Hologic by 59.6% during the second quarter. Glassman Wealth Services now owns 415 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 155 shares during the last quarter. Clear Street Markets LLC boosted its position in Hologic by 409.8% during the second quarter. Clear Street Markets LLC now owns 520 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 418 shares in the last quarter. Salem Investment Counselors Inc. grew its holdings in Hologic by 163.9% in the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 341 shares during the last quarter. Finally, CX Institutional purchased a new position in shares of Hologic in the second quarter valued at $48,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently commented on HOLX shares. SVB Leerink increased their price objective on shares of Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Friday, December 16th. Wells Fargo & Company upped their target price on Hologic from $75.00 to $80.00 and gave the company an “equal weight” rating in a research note on Tuesday. Cowen cut their price target on Hologic from $88.00 to $86.00 and set an “outperform” rating for the company in a report on Tuesday, November 1st. Finally, Morgan Stanley increased their price objective on Hologic from $68.00 to $74.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 1st. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $78.75.
Hologic Stock Up 0.1 %
Hologic (NASDAQ:HOLX – Get Rating) last posted its quarterly earnings results on Monday, October 31st. The medical equipment provider reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.20. The firm had revenue of $953.30 million during the quarter, compared to the consensus estimate of $861.68 million. Hologic had a return on equity of 31.85% and a net margin of 26.77%. The firm’s quarterly revenue was down 27.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.61 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 3.46 EPS for the current year.
Insider Buying and Selling
In other Hologic news, General Counsel John M. Griffin sold 26,902 shares of Hologic stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $76.12, for a total transaction of $2,047,780.24. Following the transaction, the general counsel now directly owns 168,944 shares of the company’s stock, valued at $12,860,017.28. The sale was disclosed in a filing with the SEC, which is available at this link. In other Hologic news, CFO Karleen Marie Oberton sold 14,545 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total value of $1,054,512.50. Following the transaction, the chief financial officer now directly owns 126,811 shares of the company’s stock, valued at $9,193,797.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel John M. Griffin sold 26,902 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $76.12, for a total value of $2,047,780.24. Following the transaction, the general counsel now owns 168,944 shares in the company, valued at approximately $12,860,017.28. The disclosure for this sale can be found here. Corporate insiders own 1.54% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.